Research Update End-Year 2 for Biomarker to Detect Lymphoma Risk, Classify for Treatment and Predict Risk

End-year 2 update of Dr. Jeffery Bryan’s research to discover biomarkers for detection, classification, and treatment of B-cell lymphoma. Progress continues in the researcher’s efforts into this population of B cell lymphomas similar to the aggressive form seen in humans.

Progress continues at all 3 institutions. The proposed immunohistochemical evaluations and flow cytometry techniques are developed and are being refined as cases are added to the
series. The population of B cell lymphomas appears to be a monomorphic group of diffuse large B cell variety (DLBCL) similar to the aggressive form in humans.

An immunohistochemistry panel is now functional to identify these and flow cytometry is being optimized. Sequencing experiments have identified a growing list of genes that are
hypermethylated in B cell lymphomas of Golden Retrievers that is similar to those in human lymphoma. TAMU has successfully generated tumor initiating cell populations from cultured
lymphocytes and has optimized the procedures to be performed on fine-needle aspirates of lymphoma nodes. It appears that multiple aspirates will be necessary to get all the material
needed for characterization. Sufficient TIC cells can be generated for sequencing with the protocol in place at MU.

The personnel for the studies are now in place. Further sequence generation is pending that will allow us to move forward with the diagnostic PCR panel. Because the lymphoma samples are so similar across the board, we are changing Aim 1 slightly to evaluate gene expression in these tumors as it relates to the methylation profile.